Sharon Shacham Net Worth

The estimated Net Worth of Sharon Shacham is at least $15.6 Миллион dollars as of 28 February 2022. Sharon Shacham owns over 12,452 units of Karyopharm Therapeutics Inc stock worth over $528,180 and over the last 11 years he sold KPTI stock worth over $12,087,507. In addition, he makes $3,020,460 as President и Chief Scientific Officer at Karyopharm Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Sharon Shacham KPTI stock SEC Form 4 insiders trading

Sharon has made over 56 trades of the Karyopharm Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 12,452 units of KPTI stock worth $127,508 on 28 February 2022.

The largest trade he's ever made was selling 200,000 units of Karyopharm Therapeutics Inc stock on 2 July 2014 worth over $8,500,000. On average, Sharon trades about 15,144 units every 43 days since 2013. As of 28 February 2022 he still owns at least 713,757 units of Karyopharm Therapeutics Inc stock.

You can see the complete history of Sharon Shacham stock trades at the bottom of the page.

Sharon Shacham biography

Dr. Sharon Shacham Ph.D. serves as President, Chief Scientific Officer of the Company. She serves as President, Chief Scientific Officer of the Company. serves as President, Chief Scientific Officer of the Company. She serves as President, Chief Scientific Officer of the Company. Dr. Shacham founded Karyopharm in 2008 and has served as our President since December 2013, and as our Chief Scientific Officer since October 2010. Dr. Shacham served as our President of Research and Development from December 2012 to December 2013, as our Head of Research and Development from October 2010 to December 2012 and as our President and Chief Executive Officer from October 2010 to January 2011. Dr. Shacham established the company to focus on the discovery and development of small molecule inhibitors of nuclear export and has led our scientific progress since inception. Her computational drug discovery algorithms formed a critical part of the technological basis for our drug discovery and optimization expertise, which was used for the discovery of selinexor, our lead drug candidate. Dr. Shacham co-chairs our Scientific Advisory Board. Prior to founding Karyopharm, from 2006 to April 2009, she was Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., a biopharmaceutical company that underwent liquidation proceedings through an assignment for the benefit of creditors under Massachusetts law in 2009. She was Director, Algorithm and Software Development at Predix Pharmaceuticals Inc. from July 2000 until Predix’s merger into Epix Pharmaceuticals in 2006, where she led the company’s efforts in GPCR modeling, computational chemistry, lead optimization and development of clinical trials. Dr. Shacham received her B.Sc. in Chemistry, Ph.D. and M.B.A. from Tel Aviv University.

What is the salary of Sharon Shacham?

As the President и Chief Scientific Officer of Karyopharm Therapeutics Inc, the total compensation of Sharon Shacham at Karyopharm Therapeutics Inc is $3,020,460. There are 2 executives at Karyopharm Therapeutics Inc getting paid more, with Ran Frenkel having the highest compensation of $6,481,860.

How old is Sharon Shacham?

Sharon Shacham is 49, he's been the President и Chief Scientific Officer of Karyopharm Therapeutics Inc since 2017. There are 17 older and 5 younger executives at Karyopharm Therapeutics Inc. The oldest executive at Karyopharm Therapeutics Inc is Garen Bohlin, 72, who is the Independent Director.

What's Sharon Shacham's mailing address?

Sharon's mailing address filed with the SEC is C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON, MA, 02459.

Insiders trading at Karyopharm Therapeutics Inc

Over the last 11 years, insiders at Karyopharm Therapeutics Inc have traded over $149,223,596 worth of Karyopharm Therapeutics Inc stock and bought 562,763 units worth $10,312,371 . The most active insiders traders include Deepika Pakianathan, Ltd Czernik Marcin Hadjimic... и Mikael Dolsten. On average, Karyopharm Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $26,350. The most recent stock trade was executed by Michael Mano on 4 September 2024, trading 3,971 units of KPTI stock currently worth $2,859.

What does Karyopharm Therapeutics Inc do?

karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com

Complete history of Sharon Shacham stock trades at Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc executives and stock owners

Karyopharm Therapeutics Inc executives and other stock owners filed with the SEC include:

• Ran Frenkel,
  Chief Development Operations Officer
• Michael Kauffman,
  Co-Founder, Chief Executive Officer and Director
• Sharon Shacham,
  President, Chief Scientific Officer
• Christopher Primiano,
  Executive Vice President, Chief Business Officer, General Counsel and Secretary
• Dr. Michael G. Kauffman M.D., Ph.D.,
  Co-Founder, Sr. Clinical Advisor & Director
• Dr. Michael G. Kauffman,
  Co-Founder, Sr. Clinical Advisor & Director
• Dr. Sharon Shacham M.B.A., Ph.D.,
  Co-Founder & Chairman of Scientific Advisory Board
• Dr. Sharon Shacham,
  Co-Founder, Chief Scientific Officer & Chairman of Scientific Advisory Board
• Michael P. Mason CPA, M.B.A.,
  Sr. VP, CFO & Treasurer
• Mansoor Mirza,
  Director and Clinical Advisor
• Barry Greene,
  Lead Independent Director
• Deepa Pakianathan,
  Independent Director
• Garen Bohlin,
  Independent Director
• Dr. Mansoor Raza Mirza M.D.,
  Clinical Consultant, Member of Scientific Advisory Board & Independent Director
• Mikael Dolsten,
  Independent Director
• Dr. Mansoor Raza Mirza,
  Clinical Consultant, Member of Scientific Advisory Board & Director
• Richard A. Paulson M.B.A.,
  Pres, CEO & Director
• Richard Paulson,
  Independent Director
• Christy Oliger,
  Director
• Perry Monaco,
  Senior Vice President of Sales
• Jatin Shah,
  Executive Vice President, Chief Medical Officer
• Tanya Lewis,
  Executive Vice President, Chief Regulatory Officer and Quality Officer
• Michael Mason,
  Chief Financial Officer, Senior Vice President, Treasurer
• James Accumanno J.D.,
  Chief Compliance Officer
• Elhan Webb C.F.A.,
  Sr. VP of Investor Relations
• Lisa Meletta J.D.,
  VP of Legal & Chief Compliance Officer
• Michael J. Mano J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Pierre S. Sayad M.S., Ph.D.,
  VP of Global Medical & Scientific Affairs
• Cameron Peters,
  VP of Fin., Assistant Treasurer & Principal Accounting Officer
• Ran Frenkel R.Ph., RPh,
  Exec. VP & Chief Devel. Officer
• Zhen Su,
  
• Carsten Thiel,
  Director
• Kenneth E Weg,
  Director
• J. Scott Garland,
  Director
• Justin A Renz,
  EVP, CFO & Treasurer
• Michael Falvey,
  EVP, CFO & Treasurer
• Peter Honig,
  Director
• Anand Varadan,
  EVP, Chief Commercial Officer
• Cameron Peters,
  VP of Finance
• Marcin Hadjimichael Andreas...,
  
• Paul Brannelly,
  SVP, FIN & ADMIN, SEC & TRES
• Ltd Czernik Marcin Hadjimic...,
  
• Ltd Czernik Marcin Hadjimic...,
  
• John Demaree,
  Chief Commercial Officer
• Deepika Pakianathan,
  
• Chen Schor,
  
• Stephen Mitchener,
  SVP, Chief Business Officer
• Michael Mano,
  SVP, General Counsel&Secretary
• Sohanya Roshan Cheng,
  EVP & Chief Commercial Officer
• Stuart Poulton,
  EVP, Chief Development Officer
• Reshma Rangwala,
  EVP & Chief Medical Officer